Verve Therapeutics Inc. (VERV)
Verve Therapeutics Statistics
Share Statistics
Verve Therapeutics has 88.8M shares outstanding. The number of shares has increased by 5.75% in one year.
Shares Outstanding | 88.8M |
Shares Change (YoY) | 5.75% |
Shares Change (QoQ) | 4.88% |
Owned by Institutions (%) | 93.39% |
Shares Floating | 66.18M |
Failed to Deliver (FTD) Shares | 225 |
FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 14.79M, so 17.47% of the outstanding shares have been sold short.
Short Interest | 14.79M |
Short % of Shares Out | 17.47% |
Short % of Float | 23.43% |
Short Ratio (days to cover) | 10.17 |
Valuation Ratios
The PE ratio is -2.39 and the forward PE ratio is -2.61. Verve Therapeutics's PEG ratio is 0.1.
PE Ratio | -2.39 |
Forward PE | -2.61 |
PS Ratio | 14.69 |
Forward PS | 17.3 |
PB Ratio | 0.96 |
P/FCF Ratio | -2.94 |
PEG Ratio | 0.1 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Verve Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.65, with a Debt / Equity ratio of 0.14.
Current Ratio | 12.65 |
Quick Ratio | 12.65 |
Debt / Equity | 0.14 |
Debt / EBITDA | -0.31 |
Debt / FCF | -0.43 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $118K |
Profits Per Employee | $-725.22K |
Employee Count | 274 |
Asset Turnover | 0.05 |
Inventory Turnover | n/a |
Taxes
Income Tax | 349K |
Effective Tax Rate | -0.18% |
Stock Price Statistics
The stock price has increased by -55.8% in the last 52 weeks. The beta is 1.78, so Verve Therapeutics's price volatility has been higher than the market average.
Beta | 1.78 |
52-Week Price Change | -55.8% |
50-Day Moving Average | 6.77 |
200-Day Moving Average | 5.97 |
Relative Strength Index (RSI) | 24.87 |
Average Volume (20 Days) | 1.46M |
Income Statement
In the last 12 months, Verve Therapeutics had revenue of 32.33M and earned -198.71M in profits. Earnings per share was -2.36.
Revenue | 32.33M |
Gross Profit | 32.33M |
Operating Income | -228.66M |
Net Income | -198.71M |
EBITDA | -228.66M |
EBIT | -228.66M |
Earnings Per Share (EPS) | -2.36 |
Balance Sheet
The company has 172.56M in cash and 69.98M in debt, giving a net cash position of 102.58M.
Cash & Cash Equivalents | 172.56M |
Total Debt | 69.98M |
Net Cash | 102.58M |
Retained Earnings | -743.01M |
Total Assets | 647.39M |
Working Capital | 499.84M |
Cash Flow
In the last 12 months, operating cash flow was -157.69M and capital expenditures -3.74M, giving a free cash flow of -161.43M.
Operating Cash Flow | -157.69M |
Capital Expenditures | -3.74M |
Free Cash Flow | -161.43M |
FCF Per Share | -1.92 |
Margins
Gross margin is 100%, with operating and profit margins of -707.23% and -614.59%.
Gross Margin | 100% |
Operating Margin | -707.23% |
Pretax Margin | -613.51% |
Profit Margin | -614.59% |
EBITDA Margin | -707.23% |
EBIT Margin | -707.23% |
FCF Margin | -499.28% |
Dividends & Yields
VERV does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for VERV is $23.5, which is 510.4% higher than the current price. The consensus rating is "Buy".
Price Target | $23.5 |
Price Target Difference | 510.4% |
Analyst Consensus | Buy |
Analyst Count | 5 |
Scores
Altman Z-Score | -0.34 |
Piotroski F-Score | 3 |